ProBioGen’s Growth Strategy Continues Successfully

ProBioGen has seen significant growth with over 300 employees now working across its three locations in Berlin.
In line with this growth, three crucial positions have been filled. Julian Collins has been appointed as Senior Vice President, Head of People & Organizational Development (P&OD) and a member of the Executive Team, while Michiel Stork has taken on a role of Vice President, Business Development (BD) and Jana Windt has filled the position as Head of Marketing & Communications (MarCom). These appointments reflect the company's commitment to continued growth.

Julian Collins leads the People & Organizational Development department at ProBioGen. With more than 20 years of human resource experience in the financial service, chemical and medical device industries, he will expand the "people" function to ensure the sustainable development of ProBioGen and MiGenTra employees as responsible drivers of the companies' goals. "By making encouraged personal development the natural working environment of both companies, we are positioning ourselves as employers of choice that attract, develop and retain the best talent for the long term - a task I am grateful to take on," Collins said.

Jana Windt comes on board as Head of Marketing & Communications. With more than 15 years of experience in diverse Marketing and Communications positions within B2B tech and healthcare companies of different sizes, she has demonstrated a track record of success in establishing and managing marketing departments with a focus on growth. Jana has herself gone through an evolution from Corporate Communications, to Product and Brand Marketing on to holistic Customer Lifecycle Marketing. "I join ProBioGen with the ambition to evolve our marketing department into a customer-centric and data-oriented revenue driver and am personally proud to become part of the company's mission to develop tomorrow's medicines."

Dr. Michiel Stork takes on the leadership of ProBioGen's growing and globally active BD team, to expand its customer base and to build long-lasting relationships. The BD team's goal is to promote ProBioGen's premium technologies and services that enable efficient production of biologics in the field of proteins and viral vectors/cell and gene therapy. Michiel is an experienced manager with an extensive scientific knowledge. As the head of Intravacc's BD team, he was responsible for overseeing the acquisition of service projects as well as out-licensing. Since receiving his PhD in molecular microbiology in 2006, he has been active in the pharmaceutical field for over 18 years. "I'm passionate about bringing scientific ideas to the market and using my knowledge of the entire value chain to help customers and ultimately patients."

"These new appointments bring three highly qualified leaders with first class expertise in their fields, as well as a passion for engaging and leading teams," stated Dr. Lutz Hilbrich, Chief Executive Officer of ProBioGen and MiGenTra. "Our vision is a world where there is treatment for every disease. With our top-notch services and technologies, we strive to make this dream a reality by empowering our clients to succeed in developing cutting-edge drugs and vaccines. Driven by the strong demand for our offerings, we plan to grow in a sustainable manner, enabling us to assist more and more clients, and ultimately, improve the lives of more patients. This calls for maintaining the highest standards in our processes, technologies, and products."

About ProBioGen

ProBioGen is a Berlin-based biotech company, so-called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.

It specializes in developing and manufacturing biopharmaceutical active ingredients and vaccines, applying proprietary technologies to improve product quality and features. It started in 1994 as a spin-off of Charité, widely recognized as the best hospital in Germany. Twenty-eight years later, over 300 employees work at ProBioGen's three locations in Berlin.

Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

For more information about ProBioGen, follow us on LinkedIn.